Invesco’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-812,737
Closed -$30.6M 4117
2021
Q1
$30.6M Sell
812,737
-864,645
-52% -$21.6M 0.01% 1298
2020
Q4
$28.5M Buy
1,677,382
+1,621,028
+2,877% +$20.3M 0.01% 1245
2020
Q3
$264K Sell
56,354
-105,501
-65% -$536K ﹤0.01% 3364
2020
Q2
$987K Buy
161,855
+98,442
+155% +$406K ﹤0.01% 2808
2020
Q1
$144K Buy
63,413
+34,946
+123% +$148K ﹤0.01% 3490
2019
Q4
$131K Sell
28,467
-1,925
-6% -$7.62K ﹤0.01% 3587
2019
Q3
$118K Sell
30,392
-1,168
-4% -$6.41K ﹤0.01% 3616
2019
Q2
$190K Sell
31,560
-13,514
-30% -$129K ﹤0.01% 3625
2019
Q1
$604K Buy
45,074
+1,493
+3% +$17K ﹤0.01% 3235
2018
Q4
$405K Buy
43,581
+5,709
+15% +$67.9K ﹤0.01% 3362
2018
Q3
$527K Buy
37,872
+30
+0.1% +$446 ﹤0.01% 3406
2018
Q2
$598K Buy
37,842
+10,759
+40% +$188K ﹤0.01% 3350
2018
Q1
$465K Buy
27,083
+11,919
+79% +$233K ﹤0.01% 3356
2017
Q4
$332K Buy
15,164
+666
+5% +$21.4K ﹤0.01% 3421
2017
Q3
$593K Buy
14,498
+226
+2% +$7.09K ﹤0.01% 3249
2017
Q2
$430K Sell
14,272
-30,477
-68% -$951K ﹤0.01% 3367
2017
Q1
$1.62M Sell
44,749
-162,152
-78% -$7.15M ﹤0.01% 2750
2016
Q4
$10.4M Buy
206,901
+32,413
+19% +$1.7M ﹤0.01% 1518
2016
Q3
$9.16M Buy
174,488
+1,577
+0.9% +$75.3K ﹤0.01% 1559
2016
Q2
$7.15M Buy
172,911
+98,933
+134% +$4.3M ﹤0.01% 1653
2016
Q1
$3.01M Buy
+73,978
New +$2.54M ﹤0.01% 2222
2015
Q3
Sell
-217
Closed -$5K 4101
2015
Q2
$5K Buy
+217
New +$4.83K ﹤0.01% 4245
2015
Q1
Sell
-41,683
Closed -$1.13M 4096
2014
Q4
$1.13M Buy
+41,683
New +$717K ﹤0.01% 2885

Invesco's FPRX Position: Q2 2021 in Review

Invesco sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 812,737 shares — an estimated $30.6M sold.

Invesco first reported a position in FPRX in Q4 2014 and held it in 23 quarters. The position peaked at $30.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Invesco reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Invesco sold 812,737 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $30.6M.
  • Invesco first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 23 quarters.
  • Invesco's Five Prime Therapeutics, Inc. position peaked at $30.6M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.